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er of chemosensitivity and that pathologic 
complete response is an important prognos-
tic factor for a longer disease-free time and 
overall survival in patients with locally ad-
vanced breast cancer (LABC) [10, 11].
The purpose of our study was to assess the 
variation in whole-breast vascular maps on 
DCE-MRI after anthracycline- and taxane-
based primary chemotherapy in patients with 
LABC and to correlate changes in breast vas-
cular maps with pathologic tumor response.
Subjects and Methods
Patients and Treatment
From January 2006 through December 2009, 
36 patients (mean age, 46 years; range, 32–63 
years) with unilateral LABC (clinical stage II 
with tumor > 3 cm or stage IIIA/B/C) diagnosed 
at mammography or ultrasound were consecutive-
ly enrolled in the study. Women with inflamma-
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T
he assessment of breast vascular-
ity obtained with dynamic con-
trast-enhanced MRI (DCE-MRI) 
represents an intriguing possibil-
ity. In fact, visualization of bilateral vascular 
maps is intrinsically integrated into a standard 
breast DCE-MRI study, without an increase 
in acquisition time or the administration of 
additional contrast material. Several authors 
have shown that an asymmetric increase in 
whole-breast vascularity is associated with ip-
silateral invasive breast cancers, with overall 
accuracy values of 73–87% [1–6].
On the other hand, in vitro studies have 
shown that inhibition of tumor growth with 
chemotherapeutic drugs, including taxanes, 
is associated with suppression of angiogen-
esis [7–9]. Moreover, it is widely accepted 
that pathologic tumor response to primary 
chemotherapy represents an in vivo mark-
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W O M E N ’ S
I M A G I N G
OBJECTIVE. The purpose of this article is to assess changes in breast vascular maps on 
dynamic contrast-enhanced MRI (DCE-MRI) after primary chemotherapy in patients with 
locally advanced breast cancer (LABC).
SUBJECTS AND METHODS. Thirty-four patients with unilateral LABC underwent 
DCE-MRI before and after anthracycline- and taxane-based primary chemotherapy. The 
number of vessels 30 mm or longer in length and 2 mm or larger in maximum transverse di-
ameter were counted on maximum intensity projections of the first subtracted phase for each 
of the two breasts. Patients achieving pathologic response or small clusters of residual cancer 
cells after primary chemotherapy were considered as responders, and those with an inferior 
pathologic response were considered as nonresponders.
RESULTS. The mean (± SD) number of vessels in the breast harboring the cancer and in the 
contralateral breast was 2.7 ± 1.3 and 1.1 ± 1.0 (p < 0.001), respectively, before primary chemo-
therapy and 1.3 ± 1.1 and 1.1 ± 1.1 (p = 0.147), respectively, after primary chemotherapy. Over-
all, primary chemotherapy was associated with a significant reduction in DCE-MRI vascular 
maps in the breast harboring the cancer only (p < 0.001). Of the 34 patients, 10 were considered 
responders and 24 were nonresponders. The mean number of vessels in the breast harboring 
the cancer changed from 2.7 ± 1.1 to 0.6 ± 0.8 for the 10 responders and from 2.7 ± 1.4 to only 
1.6 ± 0.9 for the 24 nonresponders. The mean reduction of vascular map in the breast harbor-
ing the cancer was significantly higher in responders compared with nonresponders (p = 0.017).
CONCLUSION. Before primary chemotherapy, DCE-MRI vascular maps were asym-
metrically increased ipsilaterally to the LABC. After primary chemotherapy, vascular maps 
significantly changed only in the breast harboring the cancer, with significant differences be-
tween responders and nonresponders.
Martincich et al.
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tory breast cancer (stage T4d) and metastatic dis-
ease were excluded. Clinical stage was IIA in 10 
(28%), IIB in three (8%), IIIA in 16 (44%), IIIB 
in five (14%), and IIIC in two (6%) of 36 patients.
The intended treatment for all the patients was 
a combination of doxorubicin (50 mg/m2 IV bo-
lus), followed by paclitaxel (175 mg/m2 as a 3-hour 
IV infusion). Cycles were repeated every 21 days. 
For each patient, DCE-MRI was performed before 
the initiation of primary chemotherapy and was 
repeated after the last cycle of primary chemo-
therapy. Breast surgery was scheduled within 3–4 
weeks after the last cycle of primary chemothera-
py. After surgery, the histopathologic response to 
chemotherapy was evaluated using a 5-point as-
sessment scale described by Smith et al. [12] (see 
the Histopathologic Analysis and Tumor Response 
section for details). Before entering the study, all 
the patients signed a written informed consent, 
and the study was performed in compliance with 
institutional ethical regulatory issues.
DCE-MRI
DCE-MRI was performed using a 1.5-T scanner 
(Signa Excite HDx, GE Healthcare) with a dedicat-
ed 8-channel coil (GE Healthcare) with the patient 
in prone position. After a localizer in the three or-
thogonal planes and coil calibration, a 3D gradient-
echo axial sequence (Vibrant) was performed with 
the following technical parameters: TE in phase; 
TR/TE, 5.4/2.6; flip angle, 15°; slice thickness, 2.6 
mm; matrix, 416 × 416; field of view, according to 
the breast volume; and temporal resolution, 60–90 
seconds. The sequence was performed before and 
four times continuously after contrast material ad-
ministration; a late acquisition was obtained at 8 
minutes after contrast material administration. The 
contrast-enhanced study started simultaneously 
with the bolus injection of 0.1 mmol/kg gadopen-
tate dimeglumine (Magnevist, Bayer-Schering) in 
the antecubital vein using a power injector (Spec-
tris, Medrad) at a rate of 2 mL/s, followed by a sa-
line flush of 20 mL at the same injection rate.
MRI scans were postprocessed at a worksta-
tion (Advantage Windows 4.2, GE Healthcare) us-
ing image subtraction (contrast-enhanced minus 
unenhanced) and maximum intensity projection 
(MIP) reconstruction algorithm. Breast vascular 
maps were evaluated using the MIPs obtained by 
subtracting the unenhanced series from the first 
contrast-enhanced series; this temporal series was 
adequate for the angiographic study [1].
From the 3D MIP volume, axial MIPs were ob-
tained to visualize the whole vascular maps of both 
breasts. The measurements of length and diameter 
vessels were manually performed on axial MIPs 
using electronic calipers. For each examination, 
in both breasts, the number of vessels that were 
30 mm or greater in length and 2 mm or greater in 
maximal transverse diameter was counted (Fig. 1).
According to these parameters, a vascular score 
per breast was assigned. Four grades of breast vas-
cularity were defined, ranging from 0 to 3. A score 
of 0 (absent or very low breast vascularity) was 
defined as a complete absence of vessels or the 
presence of vessels less than 30 mm in length and 
less than 2 mm in maximal transverse diameter. 
A score of 1 (low vascularity) described breasts 
with only one vessel that was 30 mm or greater in 
length and 2 mm or greater in maximal transverse 
diameter. A score of 2 (moderate vascularity) in-
dicated the presence of two to four vessels 30 mm 
or greater in length and 2 mm or greater in maxi-
mal transverse diameter. Breasts with five or more 
vessels 30 mm or greater in length and 2 mm or 
greater in maximal transverse diameter were giv-
en a score of 3 (high vascularity).
Two radiologists with 3 and 11 years of expe-
rience with breast MRI, who were blinded to fi-
nal pathologic analysis, performed in consensus 
the analysis at baseline and after the completion 
of the planned primary chemotherapy. The num-
ber of vessels and the vascular score was calculat-
ed for both breasts.
Histopathologic Analysis and Tumor Response
After surgery, breast specimens were handled ac-
cording to institutional guidelines [13]. Pathologic 
assessment included macroscopic lesion localiza-
tion in the specimen, fixation in formalin, and em-
bedding in paraffin before large-size sections were 
made. Additional sections of grossly normal breast 
tissue were prepared for patients who had undergone 
mastectomy or quadrantectomy. Specimens were ex-
amined microscopically using H and E staining.
The pathologic response to chemotherapy was as-
sessed using a 5-point assessment scheme described 
by Smith et al. [12]: grade 1, some alterations to in-
dividual malignant cells but no reduction in over-
all numbers compared with the pretreatment core 
biopsy; grade 2, a mild loss of invasive tumor cells 
but overall cellularity still high; grade 3, a consid-
erable reduction in tumor cells up to an estimated 
90% loss; grade 4, a marked disappearance of in-
vasive tumor cells such that only small clusters of 
widely dispersed cells could be detected; and grade 
5, no invasive tumor cells identifiable in the sections 
from the site of the previous tumor—that is, only in 
A
Fig. 1—54-year-old woman with large invasive ductal carcinoma in right breast. 
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situ disease or tumor stroma remained. A grade 5 re-
sponse was deemed to represent a pathologic com-
plete response of the primary cancer. In the current 
study, the patients were classified as responders if 
the pathologic tumor response to primary chemo-
therapy was grade 4 or 5 and as nonresponders if the 
grade of response ranged between 1 and 3.
Statistical Analysis
To assess whether any variation in breast vas-
cular maps occur after primary chemotherapy, the 
mean number of vessels at baseline and after pri-
mary chemotherapy was first compared by use of 
Wilcoxon matched-pairs test in both breasts in 
all the patients, regardless of response to prima-
ry chemotherapy. Subsequently, the mean num-
ber of vessels and mean vascular score after pri-
mary chemotherapy were compared in responders 
and nonresponders by the Mann-Whitney U test. 
A further analysis was performed by considering 
the vessel reduction (i.e., the number of vessels 
before primary chemotherapy minus the number 
of vessels after primary chemotherapy) at the end 
of the intended treatment between responders and 
nonresponders. Statistical significance was set at p 
less than 0.05. Calculations were performed with 
the SPSS package (version 17.0, SPSS).
Results
Patients Entering Analysis
The analysis was successfully performed for 
34 of the 36 enrolled patients. In one case, the 
treatment was interrupted after the second cy-
cle because of cardiotoxicity, and in the remain-
ing one case, the patient refused the final MRI 
examination. In the 34 patients who completed 
the planned primary chemotherapy, baseline 
DCE-MRI confirmed the presence of unilat-
eral LABC. The mean (± SD) tumor diameter 
was 45.0 ± 14.0 mm (range, 25–80 mm).
Pathologic Analysis
Of a total of 34 carcinomas, pathologic anal-
ysis defined the presence of 26 (76%) invasive 
ductal carcinomas, five (15%) invasive lobu-
lar carcinomas, and three (9%) poorly differ-
entiated carcinomas. Within a mean time of 3 
weeks after primary chemotherapy, all 34 sub-
jects underwent surgery: 23 (68%) patients un-
derwent mastectomy and 11 (32%) underwent 
conservative surgery. Ten patients were classi-
fied as responders: grade 5 response (pathologic 
complete response) was achieved in five (15%) 
patients, and grade 4 responses were observed 
in five (15%) of the 34 patients. Twenty-four pa-
tients were categorized as nonresponders: three 
(9%) with grade 1 response, 11 (32%) with grade 
2 response, and 10 (29%) with grade 3 response.
DCE-MRI Vascular Maps Analysis
Before primary chemotherapy, the num-
ber of vessels was 2.7 ± 1.3 (range, 1–6) in 
the breasts harboring the cancer and 1.1 ± 1.0 
(range, 0–4) in the contralateral breasts, show-
ing a significant increase of vasculature ipsilat-
eral to the LABC (p < 0.001). After primary 
chemotherapy, the numbers of vessels in the 
breasts harboring the cancer were not signifi-
cantly different from those in the contralater-
al breasts (Table 1). Changes of vascular maps 
on the basis of pathologic tumor response are 
shown in Table 2. In the 10 responder patients, 
the number of vessels after primary chemother-
apy in the breast harboring the cancer changed 
from 2.7 ± 1.1 (range, 1–4) to 0.6 ± 0.8 (range, 
0–2), whereas in the 24 nonresponder patients, 
the number of breast vessels varied from 2.7 ± 
1.4 (range, 1–6) to only 1.6 ± 0.9 (range, 0–4). 
Only after primary chemotherapy, the mean 
number of vessels as well as the mean vascular 
score significantly differed between responders 
and nonresponders (p = 0.015 and p = 0.020, 
TABLE 1: Dynamic Contrast-Enhanced MRI Vascular Maps Analysis in Breast 
Harboring Cancer and in Contralateral Breast, Before and After 
Primary Chemotherapy, in 34 Patients With Locally Advanced 
Breast Cancer
Time of Analysis
No. of Vessels, Mean ± SD (Range)
pBreasts Harboring Cancer Contralateral Breasts
Before primary chemotherapy 2.7 ± 1.3 (1–6) 1.1 ± 1.0 (0–4) < 0.001
After primary chemotherapy 1.3 ± 1.1 (0–4) 1.1 ± 1.1 (0–4) 0.147
p < 0.001 0.900 Not applicable
Note—p values were calculated using the Wilcoxon matched-pairs test; significance threshold was set at p < 0.05.
respectively). Similarly, the vessel reduction at 
the end of the intended treatment significant-
ly varied between responder and nonresponder 
subjects (p = 0.017). An example of responder 
patient is shown in Figure 2. An example of a 
nonresponder patient is shown in Figure 3.
Discussion
A correlation between imaging and in-
creased blood flow ipsilateral to a breast can-
cer was first postulated with thermography 
in which hyperthermia was associated with 
breast cancer [14]. More recently, several 
studies with DCE-MRI revealed a differ-
ent whole-breast vasculature associated with 
malignancy as the result of a higher number 
of larger vascular structures identified in the 
breast harboring the cancer compared with 
the contralateral healthy breast [1–6].
In our study, before primary chemotherapy, 
we found an increased number of vessels in 
the breast harboring the cancer with respect to 
the contralateral one, confirming the results of 
previous studies [1–6]. Medical neoadjuvant 
treatments are aimed at downsizing the can-
cer and exploring the in vivo chemosensitiv-
ity of the tumor cells [10, 11, 15, 16]. For pa-
tients undergoing primary chemotherapy, the 
achievement of pathologic complete response 
is considered a surrogate marker for a favor-
able long-term clinical outcome [11, 17–20].
Compared with clinical examination and 
other imaging techniques, breast MRI is the 
most accurate technique for identification of 
pathologic complete response and definition 
TABLE 2: Dynamic Contrast-Enhanced MRI Vascular Maps Analysis in Breast Harboring Cancer, Before and After Primary 
Chemotherapy, in 34 Patients With Locally Advanced Breast Cancer, by Responder or Nonresponder Status
Responder Status
No. of Vessels Score










Responder (n = 10) 2.7 ± 1.1 (1–4) 0.6 ± 0.8 (0–2) 1.8 ± 0.4 (1–2) 0.6 ± 0.8 (0–2) −2.1 ± −1.0 (−4 to −1)
Nonresponder (n = 24) 2.7 ± 1.4 (1–6) 1.6 ± 0.9 (0–4) 1.8 ± 0.5 (1–3) 1.3 ± 0.7 (0–2) −1.1 ± −1.1 (−3 to 0)
p 0.727 0.015 0.924 0.020 0.017
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of the extent of residual viable tumor [20–
23]. In addition, preliminary results with 
bevacizumab in the neoadjuvant setting 
show that DCE-MRI is a suitable tool for 
evaluating renormalization of vasculature 
as a response to antiangiogenic therapy [24].
In the current study, we evaluated whether 
breast vascular maps obtained by DCE-MRI 
might predict the tumor response after tax-
ane-based primary chemotherapy. Our results 
showed a reduction in the whole-breast vas-
culature after primary chemotherapy in the 
breast harboring the cancer, whereas no signifi-
cant changes were detected in the contralateral 
breast (Table 1). When correlating the variation 
of vascular maps with the pathologic tumor re-
sponse, we observed that the decrease in breast 
vasculature was significantly different between 
responder and nonresponder patients (Table 2). 
In fact, the mean number of vessels, as well as 
the mean vascular score and the vessels’ reduc-
tion, consistently varied only in the subjects 
who achieved a major histopathologic response 
(grade 4 or 5) after primary chemotherapy.
Reduced flow resistance and angiogenic 
stimulation have been addressed as being re-
sponsible for augmented blood flow associat-
ed with cancer [25, 26]. Tumor angiogenesis 
and tumor vascular supply are key steps in tu-
mor growth and the development of metasta-
ses; neoangiogenic peptides and the migration 
and proliferation of endothelial cells represent 
components critically involved in neoangio-
genesis [27]. Taxanes are cytotoxic drugs ca-
pable of inhibiting cell mitosis and prolifera-
tion [28, 29]. Preclinical studies have assessed 
that taxanes have strong antiangiogenic ac-
tivity [8, 9]. In particular, taxotere has been 
shown to be effective as a specific inhibitor of 
in vitro and in vivo endothelial cell migration 
by targeting the microtubule cytoskeleton [7, 
30]. The exact significance of our results is not 
completely explicable. However, knowledge 
of the mechanisms of action of taxane-based 
therapies and our evidence that there are no 
differences in vasculature of the breast harbor-
ing the cancer before primary chemotherapy 
between responders and nonresponders sup-
A
Fig. 2—37-year-old woman with large invasive ductal carcinoma in right breast: responder case. 
A, Before primary chemotherapy, dynamic contrast-enhanced MRI vascular maps analysis showed presence of three vessels 2 mm or greater in maximal transverse 
diameter and 30 mm or greater in length in breast harboring cancer (score 2). Two vessels were identifiable in contralateral breast (score 2). 
B, After treatment, score was 0 in right breast (only one vessel of 1.8 mm in maximal transverse diameter was detected) whereas result was unchanged in contralateral 
breast (two vessels of 2 mm or greater in diameter). Patient underwent conserving surgery, and grade of pathologic tumor response was equal to 4 (microscopic clusters 
of residual invasive cancer cells).
B
A
Fig. 3—42-year-old woman with large invasive ductal carcinoma in right breast: nonresponder case. 
A, Before primary chemotherapy, dynamic contrast-enhanced MRI vascular maps analysis showed increased vascularity ipsilateral to breast cancer. In right breast, 
two vessels were 2 mm or greater in maximal transverse diameter and 30 mm or greater in length (score 2), whereas no vessels 2 mm or greater in maximal transverse 
diameter and 30 mm or greater in length were detectable in contralateral healthy breast (score 0). 
B, At end of treatment, in breast harboring cancer, number of vessels as well as degree of vascularity resulted unchanged. Patient underwent mastectomy, and grade of 
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port the hypothesis that changes in vessel num-
ber and size are related to different responses 
to primary chemotherapy drugs.
To the best of our knowledge, this is the first 
study evaluating the relationship between the 
whole-breast vascularity assessed with MRI 
and the histopathologic outcome after prima-
ry chemotherapy. However, some limitations 
should be addressed. First, the definition of the 
threshold to differentiate responders from non-
responders and the comparison of vascular 
maps with other DCE-MRI findings were not 
aims of our study. As a consequence, our results 
should be considered as preliminary and require 
further investigation, including the study of the 
early predictive role of variations of vascular 
maps during primary chemotherapy. Second, 
the method adopted in our study to quantify the 
whole-breast vascular map [1], even though it 
was previously shown to give a diagnostic gain 
in breast lesion characterization [3, 5, 6], should 
be verified in terms of reproducibility. As a mat-
ter of fact, artifacts, especially those due to mis-
registration, may limit the vessel analysis. This 
event can be counteracted by looking at source 
images. Future studies in this realm should in-
clude the introduction of computer-assisted 
software performing a standardized and high-
ly reproducible quantification of breast vessels. 
Third, the temporal resolution of our technical 
protocol ranged between 60 and 90 seconds, in 
agreement with technical requirements recom-
mended in the literature [22] and adequate for 
an angiographic study [1, 3]. As a consequence, 
mixed arterial and venous vessels are also en-
hanced as a result of contrast material adminis-
tration, which may be a study limitation. How-
ever, we should also consider the evidence that 
tumor blood supply also derives from the venous 
circulation side [31].
In conclusion, our results show that whole-
breast vascular maps obtained with DCE-MRI 
can be considered as a new tool to evaluate the 
tumor response to primary chemotherapy, de-
picting variations in breast vasculature resulting 
from different responses to medical treatments. 
Further research is required to define the role 
of MRI vessel analysis in the clinical setting of 
primary chemotherapy of breast cancer.
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